Purpose: Prim ary lung tum ors in children and adolescents are uncom m on. W e report here on the clinical presentations, the m ethods of treatm ent, the results and the outcom es of a series of children with these rare tum ors.
Materials and Methods:We conducted a retrospective review on all the patients less than 19 years of age with prim ary lung tum ors and who were treated at Samsung Medical Center between 1995 and 2009. Twenty two cases of prim ary lung tumors were reviewed and the clinical-pathological inform ation concerning the tum or characteristics, the therapy and the follow-up was collected. Results: The average age of the 10 m ale patients and 12 fem ale patients was 11.5 years (range: 3 m onths to 18 years). Of the 22 prim ary lung tum ors, 18.2% (4/22) were benign, 36.4% (8/22) were of borderline m alignancy and 45.4% (10/22) were m alignant. The pathologic types were inflam m atory m yofibroblastic tum or (6/22), m ucoepiderm oid carcinom a (4), pleuropulmonary blastoma (2), adenocarcinom a (1), alveolar soft part sarcoma (1), m alignant lym phom a (1), leiom yom a (1), pulm onary leiom yom atous ham artom a (1), congenital pulm onary m yofibroblastic tum or (1), Langerhans' cell histiocytosis (1), neurilem m oma (1), sclerosing pneum ocytoma (so-called sclerosing hem angiom a) (1) and atypical carcinoid tum or (1). After surgery for the benign tumors, no postoperative recurrence was been observed during long-term follow-up. All the patients with the benign tum ors were alive with no evidence of disease. For the patients with the tum ors of borderline malignancy, one patient experienced recurrence, but there was no death from disease. For the group with m alignant tum ors, two patients died from untreatable m etastatic disease and 8 patients survived their disease on the long-term follow-up. Conclusion: The prim ary lung tum ors during childhood and adolescence had different characteristics com pared with their adult counterparts with respect to the incidence and prognosis. These facts m ust be considered when m aking the diagnosis and deciding on proper therapy. (J Lung Cancer 2009;8(2):103 110)